Epoetin alfa
Epogen/Procrit, Procrit, Retacrit (epoetin alfa) is a protein pharmaceutical. Epoetin alfa was first approved as Epogen/procrit on . It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, chronic kidney failure, and neoplasms. It is known to target erythropoietin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Epogen/procrit, Procrit, Retacrit
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anemia | EFO_0004272 | D000740 | D64.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
epoetin alfa, Epogen/Procrit, Amgen, Inc. | |||
| 1997-12-31 | Orphan excl. | ||
epoetin alfa, Procrit, Amgen, Inc. | |||
| 1997-12-31 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
Clinical
Clinical Trials
789 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | HP_0001903 | D64.9 | 11 | 103 | 128 | 68 | 50 | 352 |
| Chronic renal insufficiency | D051436 | — | N18 | 8 | 24 | 27 | 10 | 19 | 87 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 7 | 21 | 18 | 12 | 11 | 66 |
| Neoplasms | D009369 | — | C80 | 1 | 14 | 14 | 5 | 11 | 45 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 21 | 11 | 2 | 5 | 38 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 4 | 8 | 15 |
| Lymphoma | D008223 | — | C85.9 | 1 | 3 | 7 | 1 | 2 | 14 |
| Iron-deficiency anemia | D018798 | HP_0001891 | D50 | 1 | 2 | 3 | 4 | 5 | 14 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 2 | 4 | 1 | 2 | 8 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 6 | 1 | — | 8 |
Show 36 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 16 | 3 | 1 | — | 4 | 22 |
| Leukemia | D007938 | — | C95 | — | 5 | 7 | — | 1 | 13 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 5 | 4 | — | 1 | 8 |
| Plasma cell neoplasms | D054219 | — | — | — | 2 | 5 | — | 1 | 8 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | 3 | — | 3 | 7 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 4 | 2 | — | 1 | 7 |
| Cerebral palsy | D002547 | — | G80 | 1 | 2 | 1 | — | 3 | 7 |
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 4 | 3 | 3 | — | — | 7 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 4 | 2 | — | 2 | 7 |
| Blood transfusion | D001803 | — | — | — | 4 | 5 | — | 1 | 7 |
Show 70 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 5 | — | — | — | 5 |
| Ischemic stroke | D000083242 | — | — | 3 | 2 | — | — | — | 4 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 1 | — | — | 1 | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 2 | — | — | 1 | 3 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | — | — | 1 | 3 |
| Critical illness | D016638 | — | — | — | 2 | — | — | 1 | 3 |
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | 3 | — | — | — | 3 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 2 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | 1 | — | — | 1 | 2 |
| Reperfusion injury | D015427 | — | — | — | 1 | — | — | 1 | 2 |
Show 35 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 2 | 3 |
| Reticulocyte count | D017701 | — | — | 1 | — | — | — | — | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
| Autoimmune hepatitis | D019693 | — | K75.4 | 1 | — | — | — | — | 1 |
| Hypogonadism | D007006 | HP_0000044 | E23.0 | 1 | — | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
| Alveolar bone loss | D016301 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | — | 2 | 2 |
| Surgical blood loss | D016063 | — | — | — | — | — | — | 2 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 2 | 2 |
| Continuous ambulatory peritoneal dialysis | D010531 | — | — | — | — | — | — | 1 | 1 |
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
| Iron metabolism disorders | D019189 | — | E83.1 | — | — | — | — | 1 | 1 |
| Hemolytic anemia | D000743 | — | D55-D59 | — | — | — | — | 1 | 1 |
| Vitamin b 12 deficiency | D014806 | EFO_0000734 | E53.8 | — | — | — | — | 1 | 1 |
| Arthroplasty | D001178 | — | — | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Epoetin alfa |
| INN | epoetin alfa |
| Description | Erythropoietin precursor (Epoetin) |
| Classification | Protein |
| Drug class | erythropoietins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201565 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00016 |
| UNII ID | 64FS3BFH5W (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Procrit – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Retacrit – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Epoetin alfa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62,078 documents
View more details
Safety
Black-box Warning
Black-box warning for: Epogen, Mircera, Procrit, Retacrit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
50,141 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use